Richard C. Frank

3.1k citations

50 papers · 2.4k indexed · h-index 21

Hematology top 2%
- Acute Myeloid Leukemia Research 5
- Multiple Myeloma Research and Treatments 4
Oncology top 2%
- Lung Cancer Research Studies 7
- Pancreatic and Hepatic Oncology Research 6
Pathology and Forensic Medicine top 2%
Genetics top 5%
Neurology top 5%
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 6
- Prostate Cancer Treatment and Research 6
- Lung Cancer Treatments and Mutations 5
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 4

Co-authors: Stephen D. Nimer Patrick Lemaire Hideo Uchida Hendrik G. Stunnenberg Patrick Charnay Christine Vesque J. Schmitt Shifeng Mao
Cited by: Hematology Oncology Pathology and Forensic Medicine
Journals: Nucleic Acids Research (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Oncology (12 papers)
Partner nations: United States Netherlands Germany

In The Last Decade

Richard C. Frank

48 papers receiving 2.4k citations

Peers

Countries citing papers authored by Richard C. Frank

Since Specialization

Citations

This map shows the geographic impact of Richard C. Frank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Frank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Frank more than expected).

Fields of papers citing papers by Richard C. Frank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Frank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Frank. The network helps show where Richard C. Frank may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard C. Frank, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard C. Frank Line = papers co-authored together Richard C. Frank links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study The Journal of Clinical Endocrinology & Metabolism ·Richard C. Frank,Brian Shim,Tammy Lo,Deep Pandya,Thorsten Krebs,Marie‐Aline Charles,Daniel M. Labow,Jill Denowitz,Naveen Anand,Pramila Krumholtz,Kiyoe Sullivan,Mark Sanchez,Xiang Da Dong,Ramanathan Seshadri,Antolin C. Trinidad,Dugho Jin	2025	3
2	A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies. Journal of Clinical Oncology ·Frank Tsai,Michael J. Birrer,Jason R. Brown,Sanjay Chandrasekaran,Vincent Chung,Richard C. Frank,Edward G. Garmey,Shirish M. Gadgeel,Thomas J. George,Shadia I. Jalal,Andrew Poklepovic,Jennifer Segar,Alexander I. Spira,Jue Jillian Zhang,Anup Kasi	2024	2
3	Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology ·Michael T. Schweizer,Konstantin Penkov,Atish D. Choudhury,Emiliano Calvo,Richard C. Frank,Li Liu,Rajendar K. Mittapalli,Jessica Tougias,Claudia Andreu‐Vieyra,Timothy G. Bowler,Neelesh Soman,Benjamin Garmezy	2024	4
4	Abstract B012: Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer: initial results of safety and feasibility of the medically supervised ketogenic diet Cancer Research ·Gayle Jameson,Erkut Borazanci,Diana L. Hanna,Caroline G. P. Roberts,Meredith S. Pelster,Richard C. Frank,Angela Alistar,Julia E. Wiedmeier,Sandra Algaze,Brandon Fell,Sarah J. Hallberg,Denise J. Roe,Betsy C. Wertheim,Derek Cridebring,Joshua D. Rabinowitz,Stephen Gately,Daniel D. Von Hoff,Drew Rasco	2024	1
5	488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC) Annals of Oncology ·Michael T. Schweizer,K.D. Penkov,A.W. Tolcher,Atish D. Choudhury,Vadim Doronin,Raid Aljumaily,E. Calvo,Richard C. Frank,John Hamm,Víctor Moreno,Vladimir Vorobyev,Stephane Billotte,Timothy Bowler,J. Chen,Tsung H. Lin,LI Liu,Arnab K. Maity,Sheena Sharma,Melissa L. Johnson	2022	4
6	Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors Molecular Cancer Therapeutics ·Suresh S. Ramalingam,Marwan Fakih,John H. Strickler,Ramaswamy Govindan,Bob T. Li,Sarah B. Goldberg,David R. Gandara,Timothy F. Burns,Minal Barve,Catherine A. Shu,Richard C. Frank,Davendra Sohal,Pegah Jafarinasabian,Tian Dai,Omar Mather,David S. Hong	2021	28
7	Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance Molecular Case Studies ·Deep Pandya,Myra Shah,Fuat Kaplan,Candice Martino,Gillian H. Levy,Mia Kazanjian,Stephen Batter,John A. Martignetti,Richard C. Frank	2021	10
8	Glycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer Frontiers in Oncology ·Ipek Alpertunga,Rabail Sadiq,Deep Pandya,Tammy Lo,Maxim Dulgher,Sarah Evans,Bridget Bennett,Nancy J. Rennert,Richard C. Frank	2021	11
9	Subacute cutaneous lupus erythematosus induced by gemcitabine in 2 patients with pancreatic cancer JAAD Case Reports ·Matthew A. Cornacchia,Alexandra J. Coromilas,Stephanie M. Gallitano,Richard C. Frank,Charles L. Halasz	2019	7
10	Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration The Oncologist ·Julia A. Elvin,Laurie M. Gay,Rita Ort,Joseph Shuluk,Jennifer M. Long,L Berger Shelley,Ronald Lee,Zachary R. Chalmers,Garrett M. Frampton,Siraj M. Ali,Alexa B. Schrock,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Richard C. Frank	2017	41
11	The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer Cancer Chemotherapy and Pharmacology ·Geoffrey I. Shapiro,Richard C. Frank,Uday B. Dandamudi,Thomas Hengelage,Lily Zhao,Lucien Gazi,Maria Grazia Porro,Margaret M. Woo,Lionel D. Lewis	2011	30
12	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report BMC Cancer ·Kabir Mody,Edward B. Strauss,Robert Lincer,Richard C. Frank	2010	10
13	Fighting Cancer with Knowledge and Hope: A Guide for Patients, Families, and Health Care Providers Richard C. Frank	2009	1
14	Optimization and characterization of tRNA-shRNA expression constructs Nucleic Acids Research ·Lisa Scherer,Richard C. Frank,John J. Rossi	2007	35
15	Response of carcinoma of unknown primary site affecting bone to thalidomide The Lancet Oncology ·Richard C. Frank,Fred M. Kaplan,Saraswathi Nair	2005	4
16	Inhibition of the Transforming Growth Factor β1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein Journal of Biological Chemistry ·Andrzej Jakubowiak,Célio Pouponnot,Francisco J. Berguido,Richard C. Frank,Shifeng Mao,Joan Massagué,Stephen D. Nimer	2000	74
17	Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias Molecular and Cellular Biology ·Shifeng Mao,Richard C. Frank,Jin Zhang,Yasushi Miyazaki,Stephen D. Nimer	1999	112
18	The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1 Oncogene ·Richard C. Frank,Xiao‐Jian Sun,Francisco J. Berguido,Andrzej Jakubowiak,Stephen D. Nimer	1999	44
19	Critical Checking of the Radiological Diagnosis of ‘Complete Remission’ and ‘Partial Remission’ Following Induction Chemotherapy of Small-Cell Lung Cancer in the Light of Postoperative Histological Examination The Thoracic and Cardiovascular Surgeon ·Ludwig Müller,G Salzer,Dieter zur Nedden,Richard C. Frank,Elisabeth Müller‐Holzner	1992	4
20	Retroactive inhibition, spontaneous recovery, and type of interpolated learning. Journal of Experimental Psychology ·Donald J. Lehr,Richard C. Frank,David W. Mattison	1972	8

About Richard C. Frank

Richard C. Frank is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine, having authored 50 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Advanced Breast Cancer Therapies (6 papers), Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (5 papers), Acute Myeloid Leukemia Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Multiple Myeloma Research and Treatments (4 papers). The work is most often cited by research in Hematology (504 citations), Oncology (986 citations) and Pathology and Forensic Medicine (616 citations). Richard C. Frank has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Stephen D. Nimer, Patrick Lemaire, Hideo Uchida, Hendrik G. Stunnenberg, Patrick Charnay, Christine Vesque, J. Schmitt, Shifeng Mao, Scott W. Hiebert and Yasushi Miyazaki. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact